Spots Global Cancer Trial Database for mtor
Every month we try and update this database with for mtor cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Everolimus in Castrated Resistant Prostate Cancer(CRPC)Patients With PI3K-AKT-mTOR Signaling Pathway Deficiency | NCT03580239 | Prostate Cancer | Everolimus Placebo | 18 Years - 75 Years | Tianjin Medical University Second Hospital | |
| Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1) | NCT00789828 | Tuberous Sclero... Subependymal Gi... | Everolimus Placebo | - | Novartis | |
| Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM) | NCT00790400 | Tuberous Sclero... Lymphangioleiom... | Everolimus (RAD... Everolimus Plac... | 18 Years - | Novartis | |
| Everolimus in Castrated Resistant Prostate Cancer(CRPC)Patients With PI3K-AKT-mTOR Signaling Pathway Deficiency | NCT03580239 | Prostate Cancer | Everolimus Placebo | 18 Years - 75 Years | Tianjin Medical University Second Hospital | |
| Everolimus for Cancer With TSC1 or TSC2 Mutation | NCT02201212 | TSC1 TSC2 Tuberous Sclero... MTOR | Everolimus | 18 Years - | Dana-Farber Cancer Institute | |
| A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3) | NCT01234857 | Breast Cancer | ridaforolimus +... exemestane ridaforolimus dalotuzumab | 18 Years - | Merck Sharp & Dohme LLC | |
| Everolimus Plus Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma | NCT00869999 | Diffuse Large B... | Everolimus rituximab | 18 Years - | Massachusetts General Hospital | |
| Topical Rapamycin to Erase Angiofibromas in TSC | NCT01526356 | Angiofibromas Tuberous Sclero... | Placebo Rapamycin Rapamycin | - | The University of Texas Health Science Center, Houston | |
| A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3) | NCT01234857 | Breast Cancer | ridaforolimus +... exemestane ridaforolimus dalotuzumab | 18 Years - | Merck Sharp & Dohme LLC | |
| Trial of Efficacy and Safety of Sirolimus in Tuberous Sclerosis and LAM | NCT00490789 | Tuberous Sclero... Lymphangioleiom... | sirolimus | 18 Years - 65 Years | Cardiff University | |
| Immunosuppression in Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma | NCT00355862 | Hepatocellular ... | CNI, MMF, Stero... Sirolimus | 18 Years - | University of Regensburg | |
| Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery | NCT02315625 | Neuroendocrine ... Neuroendocrine ... Neuroendocrine ... Carcinoma, Neur... Neuroendocrine ... | Sunitinib Everolimus | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Study of BEZ235 in Adult Japanese Patients With Advanced Solid Tumors | NCT01195376 | Advanced Solid ... | BEZ235 | 20 Years - | Novartis | |
| Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study | NCT05104983 | Tuberous Sclero... Epilepsy | Sirolimus Placebo | 1 Day - 6 Months | Children's Hospital Medical Center, Cincinnati | |
| Trial of Efficacy and Safety of Sirolimus in Tuberous Sclerosis and LAM | NCT00490789 | Tuberous Sclero... Lymphangioleiom... | sirolimus | 18 Years - 65 Years | Cardiff University | |
| Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML) | NCT01184898 | AML | Sirolimus Mitoxantrone Etoposide Cytarabine | 18 Years - | Thomas Jefferson University | |
| Phase I Study to Determine the Maximum Tolerate Dose (MTD) of BGT226 in Advanced Solid Tumors in Japan | NCT00742105 | Cancer Solid Tumor Advanced Solid ... | BGT226 | 20 Years - | Novartis | |
| Everolimus in Castrated Resistant Prostate Cancer(CRPC)Patients With PI3K-AKT-mTOR Signaling Pathway Deficiency | NCT03580239 | Prostate Cancer | Everolimus Placebo | 18 Years - 75 Years | Tianjin Medical University Second Hospital | |
| Efficacy and Safety of Sirolimus in LAM | NCT00414648 | Lymphangioleiom... | Sirolimus Placebo | 18 Years - | University of Cincinnati | |
| Everolimus Plus Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma | NCT00869999 | Diffuse Large B... | Everolimus rituximab | 18 Years - | Massachusetts General Hospital | |
| Long Term Follow Up for RAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis (TSC) and Sporadic Lymphangioleiomyomatosis (LAM) | NCT00792766 | Tuberous Sclero... Angiolipoma | everolimus (RAD... | 18 Years - 65 Years | Children's Hospital Medical Center, Cincinnati | |
| Phase I Study to Determine the Maximum Tolerate Dose (MTD) of BGT226 in Advanced Solid Tumors in Japan | NCT00742105 | Cancer Solid Tumor Advanced Solid ... | BGT226 | 20 Years - | Novartis | |
| Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1) | NCT05103358 | Tumor Tumor, Solid Metastasis Metastatic Canc... Cancer Cancer Metastat... Tumors Neoplasms Neoplasm Metast... Solid Tumor Advanced Solid ... Advanced Cancer Malignant Solid... Malignant Solid... Malignant Neopl... Malignant Tumor TSC TSC1 TSC2 Metastatic Soli... Metastatic Neop... | nab-sirolimus | 12 Years - | Aadi Bioscience, Inc. | |
| Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study | NCT05104983 | Tuberous Sclero... Epilepsy | Sirolimus Placebo | 1 Day - 6 Months | Children's Hospital Medical Center, Cincinnati | |
| Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1) | NCT05103358 | Tumor Tumor, Solid Metastasis Metastatic Canc... Cancer Cancer Metastat... Tumors Neoplasms Neoplasm Metast... Solid Tumor Advanced Solid ... Advanced Cancer Malignant Solid... Malignant Solid... Malignant Neopl... Malignant Tumor TSC TSC1 TSC2 Metastatic Soli... Metastatic Neop... | nab-sirolimus | 12 Years - | Aadi Bioscience, Inc. | |
| Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas | NCT02987959 | Soft-tissue Sar... | TAK-228 | 18 Years - | Fox Chase Cancer Center | |
| Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer | NCT01347866 | Advanced Cancer | PF-05212384 PD-0325901 PF-05212384 irinotecan | 18 Years - | Pfizer | |
| Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery | NCT02315625 | Neuroendocrine ... Neuroendocrine ... Neuroendocrine ... Carcinoma, Neur... Neuroendocrine ... | Sunitinib Everolimus | 18 Years - | National Institutes of Health Clinical Center (CC) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
